R&D Expenses-2012: Pharmaceutical companies are out of step

Total R&D costs are growing, while pharmaceutical companies' R&D budgets are shrinking
Weekly Pharmacy www.apteka.ua according to The Wall Street Journal: R&D Spending to Continue ClimbingAccording to the results of a study conducted by the American private non-profit research organization Battelle Memorial Institute, despite the economic downturn, it is expected that the United States, European and Asian countries will increase R&D spending in 2012.

Battelle Memorial Institute conducted a survey among representatives of 713 companies from 63 countries. It is predicted that the growth in global R&D spending next year will amount to 5.2% and reach 1.4 trillion US dollars. It is expected that the increase in this indicator in the USA will be marked at the level of 2.1%, in Europe – 3.5%. The largest increase is projected for Asian countries, where this figure may reach 8.6%.

In addition, it is expected that in the United States, companies' spending on R&D may increase by 3.8% and reach $ 279.7 billion – this increase is the highest in the last 10 years.

Along with the growth of total R&D expenses, pharmaceutical companies plan to reduce the volume of investments in this business segment. For example, Pfizer announced plans to reduce its R&D budget from $9.4 billion in 2010 and 8.1-8.4 billion in 2010 to 6.5 billion in 2012.

The report published by the Battelle Memorial Institute notes that such a change in business strategy on the part of pharmaceutical companies opens up great opportunities in the R&D development segment for research institutions, non-profit organizations and government agencies.

On the Battelle Memorial Institute website, you can read a short summary of the report (Battelle-R&D magazine annual global funding forecast predicts R&D spending growth will continue while globalization accelerates) and its full text – VM.

Portal "Eternal youth" http://vechnayamolodost.ru
20.12.2011